Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21695252 | 0.73 | NOTUM (0.33) | KCNK3NOTUMPOLB | |
| SCHEMBL20275114 | 0.73 | NOTUM (0.33) | KCNK3NOTUMPOLB | |
| SCHEMBL16691883 | 0.71 | NOTUM (0.32) | KCNK3NOTUMPOLB | |
| SCHEMBL20738534 | 0.68 | NOTUM (0.56) | NOTUMPOLB | |
| SCHEMBL20738530 | 0.68 | NOTUM (0.56) | NOTUMPOLB | |
| SCHEMBL419149 | 0.68 | NOTUM (0.56) | NOTUMPOLB | |
| SCHEMBL220386 | 0.65 | — | — | |
| SCHEMBL14145678 | 0.65 | — | — | |
| SCHEMBL10174355 | 0.64 | SMN1; SMN2 (0.37) | NOTUMPOLB | |
| SCHEMBL14639709 | 0.64 | SMN1; SMN2 (0.37) | NOTUMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016812-A1 | NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180134717-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134717-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | HDAC10, PBDC1, PDCD10 | KCNK3 3959/4885NOTUM 4713/4885POLB 206/4885 |
| US-20190016812-A1 | NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE | TNFRSF9, TNFRSF1A, TNFSF11 | KCNK3 4517/4885NOTUM 4186/4885POLB 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.